MBM-55

SKU: orb1309444

Description

MBM-55

Research Area

Cardiovascular Research, Cell Biology, Epigenetics & Chromatin, Signal Transduction, Stem Cell & Developmental Biology

Key Properties

• CAS Number: 2083622-09-5
• MW: 498.55
• Purity: 99.98% (May vary between batches)
• Formula: C₂₈H₂₇FN₆O₂
• SMILES: CN(C)CCn1cc(cn1)-c1ccn2c(cnc2c1)-c1ccc(C(N)=O)c(OCc2cccc(F)c2)c1
• Target: S6 Kinase,Bcr-Abl,MAPK,Aurora Kinase,GSK-3,DYRK,Chk,CDK,Akt,Apoptosis
• Solubility: DMSO:120 mg/mL (240.7 mM)

Bioactivity

• Target IC50:
  NEK2:1 nM |CDK2:370 nM |GSK-3β:91 nM |Akt1:608 nM |RSK1:5.4 nM |Abl:20 nM |CDK4:441nM |Chk1:57 nM |Aurora A:5300 nM |DYRK1A:6.5 nM
• In Vivo:
  In female BALB/c nu/nu mice bearing HCT-116 xenografts, MBM-55 (20 mg/kg; i.p.) exhibits good antitumor activity and a well-tolerated dose schedule. MBM-55 (1.0 mg/kg; i.v.) shows the CL, Vss, T1/2, AUC0-t, and AUC0-∞ values of 33.3 mL/min/kg, 2.53 L/kg, 1.72 hours, 495 ng/h/mL and 507 ng/h/mL, respectively.
  Read more...
• In Vitro:
  MBM-55 (0.5-1 μM; 24 hours) induces G2/M phase arrest and accumulation of cells with >4N content in HCT-116 cells. MBM-55 (0.5-1 μM; 24 hours) causes cell apoptosis in a concentration-dependent manner in HCT-116 cells.MBM-55 inhibits MGC-803, HCT-116, Bel-7402 cells proliferation with IC50s of 0.53, 0.84, 7.13 μM, respectively.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

cell, CDK4, CDK2, CHK1, cycle, DYRK1a, Apoptosis, arrest, Aurora A, Aurora Kinase, AuroraKinase, antitumor, AKT1, BcrAbl, ABL, GSK-3β, GSK3, MBM 55, MBM55, MBM-55, Nek2, NEK2, Inhibitor, inhibit, selectivity, S6 Kinase, S6Kinase, RSK1, proliferation

Compound Identifiers

PubChem CID

137636872